Amylyx Pharmaceuticals, Inc.
amylyx.comWhat Do They Do?
Develops investigational therapies for endocrine conditions and neurodegenerative diseases, including treatments for post-bariatric hypoglycemia, Wolfram syndrome and ALS.
10-K for FY2025, filed Mar 3, 2026Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to…View ↗
We are a clinical-stage pharmaceutical company with a mission to develop novel therapies for communities with high unmet medical needs. We…View ↗
In addition to avexitide, we are advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$43.4MView ↗
- ▲ +5% (Loss)
- vs −$41.4M in Q2 FY2025
-
Aug 18, 2026
Phase 3 LUCIDITY trial met its primary and secondary endpoints
Amylyx plans to submit an application to the FDA by the end of 2026.
Sources
8-K, filed Aug 18, 2026
On August 18, 2026, the Company announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind…View ↗
Product portfolio
The older report presents a medicine as approved and marketed for ALS in the United States and Canada and says Amylyx was developing it for other neurodegenerative diseases; the latest report describes the former ALS product as discontinued and places the medicine in development for Wolfram syndrome.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 3, 2026
Broader disease focus
The older report centers on neurodegenerative diseases; the current report describes programs in both endocrine conditions and neurodegenerative diseases, including treatments aimed at PBH.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 3, 2026
Loading...
